Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11H
cell-based screening using primary human hepatocytes
InChi: InChI=1S/C14H11N3O/c18-14(10-4-2-1-3-5-10)17-13-8-11-6-7-15-12(11)9-16-13/h1-9
2-hydroxyglutarate (2HG)
ABT-199 - BCL-2 inhibitor. CAS# 1257044-40-8 Catalog No.:M60075-10S 20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11HABT 199, CAS No. 1257044 40 8, is a highly potent, selective, and orally bioavailable BCL 2 inhibitor. ABT 199 has picomolar affinity for BCL 2 (Ki < 0. 010 nM) and > 1000 folds selectivity over BCL XL (Ki = 48 nM) and BCL W (Ki = 245 nM). Therefore, ABT 199 is a much improved lead compound over the original ABT 263 (navitoclax) to avoid thrombocytopenia caused by BCL XL inhibition. ABT 199s cell killing effect is selective and mechanism dependent. It
US$ 31.99
US$ 95.00
US$ 44.00
US$ 15.99
US$ 24.99
US$ 15.00
US$ 175.00
US$ 75.00